Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

ETR/4AB stock hub

ETR/4AB has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ETR/4ABis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

302.5B

Deutsche Börse Xetra

Market data

Live price

Current market quote for this ticker.

Current price

ETR/4AB

In the news

Latest news · ETR/4AB

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E13.5

P25 12.3P50 15.7P75 20.2

Trailing P/E97

P25 16.4P50 20.9P75 30.4

ROEn/a

P25 -6.7P50 8.5P75 17.2

ROIC22.8

P25 -1.7P50 8.5P75 17.4

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ETR/4AB market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

228

Groups with data

Currency

USD

Showing 228 of 228 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	57,000
Employees Change	5,000%
Employees Change Percent	10
Enterprise value	EUR 356.5B
Exchange	Deutsche Börse Xetra
Financial currency	USD
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	US00287Y1091
Last refreshed	2026-05-10
Market cap	EUR 302.5B
Price	EUR 171
Price currency	EUR
Rev Per Employee	955,840.68x
Sector	Healthcare
Sic	2836
Symbol	etr/4AB
Website	https://www.abbvie.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.03%
EV Earnings	114.35x
EV/EBIT	19.18x
EV/EBITDA	13.85x
EV/FCF	20.58x
EV/Sales	6.68x
FCF yield	5.73%
Forward P/E	13.5x
P/B ratio	-52.76x
P/E ratio	97.03x
P/S ratio	5.55x
PE Ratio10 Y	39.99x
PE Ratio3 Y	77.83x
PE Ratio5 Y	56.73x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	34.83%
EBITDA Margin	47.62%
FCF margin	31.81%
Gross margin	72.03%
Gross Profit	EUR 39.2B
Gross Profit Growth	11.06%
Gross Profit Growth Q	15.45%
Gross Profit Growth3 Y	3.97%
Gross Profit Growth5 Y	5.95%
Net Income	EUR 3.1B
Net Income Growth	-13.35%
Net Income Growth Q	-45.96%
Net Income Growth Years	0%
Net Income Growth3 Y	-21.86%
Net Income Growth5 Y	-6.73%
Pretax Margin	9.51%
Profit Margin	5.79%
Profit Per Employee	EUR 54,701
Profitable Years	17
ROA	10.03
Roa5y	8.68
ROCE	23.19
Roe5y	1,295.2
ROIC	22.83
Roic5y	22.84

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	15.36%
Cagr1y	5.82%
Cagr3y	12.05%
Cagr5y	16.76%
Div CAGR3	1.18%
Div CAGR5	6.56%
EPS Growth	-13.24
EPS Growth Q	-46.25
EPS Growth Years	0
EPS Growth3 Y	-21.78
EPS Growth5 Y	-6.98
FCF Growth	29.87%
FCF Growth Q	154.57%
FCF Growth3 Y	-5.29%
FCF Growth5 Y	2.35%
OCF Growth	29.41%
OCF Growth Q	134.19%
OCF Growth10 Y	10.14%
OCF Growth3 Y	-4.32%
OCF Growth5 Y	2.62%
Revenue Growth	9.5x
Revenue Growth Q	12.43x
Revenue Growth Quarters	9x
Revenue Growth Years	2x
Revenue Growth3 Y	3.45x
Revenue Growth5 Y	4.59x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.46
Assets	EUR 118.4B
Cash	EUR 8.1B
Current Assets	EUR 28.4B
Current Liabilities	EUR 35.7B
Debt	EUR 63.2B
Debt EBITDA	EUR 2.41
Debt FCF	EUR 3.65
Equity	EUR -5.7B
Interest Coverage	7.52
Liabilities	EUR 124.1B
Long Term Assets	EUR 89.9B
Long Term Liabilities	EUR 88.4B
Net Cash	EUR -55.1B
Net Cash By Market Cap	EUR -18.21
Net Debt EBITDA	EUR 2.12
Net Debt FCF	EUR 3.18
Tangible Book Value	EUR -80.7B
Tangible Book Value Per Share	EUR -45.7
WACC	5.32

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.8
Inventory Turnover	3.67
Net Working Capital	EUR -8.3B
Quick ratio	0.52
Working Capital	EUR -7.4B
Working Capital Turnover	EUR -6.3

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.04%
Dividend Growth	-1.77%
Dividend Growth Years	7%
Dividend per share	EUR 5.78
Dividend Years	8
Dividend Yield	3.38%
Ex Div Date	2026-04-15
Last Dividend	EUR 1.47
Payout Frequency	Quarterly
Payout Ratio	325.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	317.32%
1Y total return	5.81%
200-day SMA	186.8
3Y total return	40.7%
50-day SMA	183
50-day SMA vs 200-day SMA	50under200
5Y total return	116.98%
All Time High	207
All Time High Change	-17.54%
All Time High Date	2025-10-02
All Time Low	41
All Time Low Change	316.34%
All Time Low Date	2014-10-15
ATR	4.13
Beta	0.31
Ch YTD	-13.17
High	173.9
High52	207
High52 Date	2025-10-02
High52ch	-17.54%
Low	170.4
Low52	155.2
Low52 Date	2025-06-30
Low52ch	9.99%
Ma50ch	-6.72%
Price vs 200-day SMA	-8.61%
RSI	40.91
RSI Monthly	48.25
RSI Weekly	38.5
Sharpe ratio	0.19x
Sortino ratio	0.49
Total Return	3.34%
Tr YTD	-11.75
Tr1m	-1.56%
Tr1w	-3.48%
Tr3m	-6.96%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 19B
Operating Income Growth	20.85
Operating Income Growth Q	18.82
Operating Income Growth3 Y	0.72
Operating Income Growth5 Y	5.79
Operating margin	34.83

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,763,680,450%
Net Borrowing	2,227,596,174
Shares Insiders	0.07%
Shares Institutions	76.02%
Shares Qo Q	0%
Shares Yo Y	0.04%
Short Ratio	3.15

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 16.5B
Average Volume	592.1x
Bv Per Share	-3.27
CAPEX	EUR -1.1B
Ch10y	212.5
Ch1m	-2.37
Ch1w	-3.48
Ch1y	2.46
Ch3m	-7.73
Ch3y	26.35
Ch5y	79.87
Ch6m	-9.78
Change	-0.99%
Change From Open	-1.59
Close	172.4
Days Gap	0.61
Depreciation Amortization	6,814,222,632
Dollar Volume	149,703.9
Earnings Date	2026-04-29
EBIT	EUR 19B
EBITDA	EUR 25.9B
EPS	EUR 1.76
F Score	8
FCF	EUR 17.3B
FCF EV Yield	4.86x
Financing CF	-9,147,413,100
Fiscal Year End	December
Founded	2,012
Goodwill	30,162,008,340
Income Tax	EUR 2B
Investing CF	-5,621,838,600
Is Primary Listing	0
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Lynch Fair Value	EUR 8.8
Lynch Upside	-94.85
Ma150	189.8
Ma150ch	-10.07%
Ma20	174.5
Ma20ch	-2.2%
Net CF	3,656,536,800
Open	173.5
P FCF Ratio	17.46
P OCF Ratio	16.44
Payment Date	2026-05-15
Position In Range	8.57
Ppne	4,822,359,894
Price Date	2026-05-08
Price EBITDA	EUR 11.66
Relative Volume	1.53x
Revenue	54,482,918,700x
SBC By Revenue	1.57x
Share Based Comp	857,759,700
Tax By Revenue	3.72x
Tax Rate	39.06%
Tr6m	-8.29%
Volume	877
Z Score	2.29

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

ETR/4AB dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+3.4%

$5.78 annual per share

Payout ratio

+325.1%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+6.6%

7 consecutive years of growth

Total shareholder yield

+3.3%

Next ex-dividend date: 2026-04-15

Performance

ETR/4AB stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ETR/4AB?

Insider, institutional, and short-interest positioning.

Institutional ownership

+76.0%

Share of float held by funds and institutions

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ETR/4AB momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

40.9

Neutral momentum band

Price vs 200-day MA

-8.6%

50/200-day relationship not available

Beta (5Y)

0.30

Less volatile than the market

Sharpe ratio

0.19

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ETR/4AB

Hub-level FAQ points readers to the deeper analysis pages.

What is the current etr/4AB stock rating?

etr/4AB is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full etr/4AB analysis?

The full report lives at /stocks/etr/4AB/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for etr/4AB?

The latest report frames etr/4AB around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the etr/4AB page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.